The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).
Bastian von Tresckow
No relevant relationships to disclose
Stefan Gundermann
No relevant relationships to disclose
Dennis A. Eichenauer
No relevant relationships to disclose
Walter Erich Aulitzky
No relevant relationships to disclose
Mariele Göbeler
No relevant relationships to disclose
Cyrus Sayehli
No relevant relationships to disclose
Liza Bacchus
No relevant relationships to disclose
Bernhard Hauns
Employment or Leadership Position - 4SC
Anna Mais
No relevant relationships to disclose
Bernd Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Hella Kohlhof
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Rolf Krauss
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Babett Krauss
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Roland Baumgartner
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Daniel Vitt
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Andreas Engert
Other Remuneration - 4SC